B Riley FBR

Concerned About The Election? Take Profits Off The Table Now, Strategist Says

Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race

Mastercraft Boat Rides Upgrade After Analyst Is 'Increasingly Confident' Demand Is Intact

Novavax Analyst Sees Leading Contender In Coronavirus Vaccine Race

Mastercraft Boat Rides Upgrade After Analyst Is 'Increasingly Confident' Demand Is Intact

Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development

Spectrum Pharma Analyst Says Sell-Off May Have Been Overdone

Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development

|

Spectrum Pharma Analyst Says Sell-Off May Have Been Overdone

|

Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

|

The Street Debates What To Do With Yelp Stock After Q4 Beat

|

B Riley FBR Recent News

The Midterm Election: What 3 Pros Expect

|

Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade

|

FBR: Novavax Looks Healthy Ahead Of Catalysts

|

Ahoy, Upside Ahead: B Riley FBR Out Bullish On 3 Shipping Stocks

|

Analysts React To Weight Watcher's Q2 Earnings

|

Pluristem Therapuetics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

|

Columbia Sportswear Downgraded Ahead Of Q2 Print

|

Farmland Partners Loans Are 'Concerning, But Immaterial,' Analyst Says In Upgrade

|

Broadcom Shares Plummet After Wall Street Questions Sudden Acquisition Strategy

|

Analyst: Tetra Technologies Is An 'EBITDA Engine'

|

Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

|

B. Riley FBR: 3 Reasons To Buy Alimera Sciences

|

3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

|

Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain

|

HomeStreet Cost Cuts Should Result In Higher 2019 Earnings, Analyst Says In Upgrade

|

Ramaco Resources Holds 25% Upside Potential, Analyst Says In Bullish Initiation

|

Analysts Applaud Intel's Q1 Beat-And-Raise, Say Delay In 10-Nanometer Chips A Negative

|

Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease

|

Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation

|

After Nvidia Analyst Day, Wall Street Talks AV Testing, Artificial Intelligence, GPUs

|

Main Street Capital Has The Ingredients For Superior Economic Return, Says B Riley FBR

|

JD Sports' $588-Million Finish Line Purchase Is Positive For Both Companies

|

BB&T Should Trade At Premium To Other Large-Cap Banks, Says B Riley FBR

|